SELLAS Life Sciences
50 hedge funds and large institutions have $5.02M invested in SELLAS Life Sciences in 2017 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 17 increasing their positions, 4 reducing their positions, and 8 closing their positions.
1,190% more call options, than puts
Call options by funds: $1.34M | Put options by funds: $104K
325% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 4
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
17% more capital invested
Capital invested by funds: $4.27M → $5.02M (+$746K)
14% more funds holding
Funds holding: 44 → 50 (+6)
0% more ownership
Funds ownership: 0.01% → 0.02% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.7M |
| 2 |
Renaissance Technologies
New York
|
+$1.77M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.24M |
| 4 |
BlackRock
New York
|
+$752K |
| 5 |
Goldman Sachs
New York
|
+$227K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$358K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$34.8K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$34.8K |
| 4 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$25K |
| 5 |
AS
Arxis Securities
New York
|
-$25K |
SLS Hedge Fund Activity: Q1 2017 in Review
50 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q1 2017, worth a combined $5.02M — up 17% from $4.27M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SLS positions and 8 closed out — a net gain of 10 holders — while 17 added to existing stakes and 4 trimmed.
The largest buyer was Sabby Management, adding an estimated $2.7M. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $358K sold.
- 50 institutional investors held SELLAS Life Sciences (SLS) as of Q1 2017, up from 44 in Q4 2016.
- Funds reported $5.02M of SELLAS Life Sciences stock for Q1 2017, up 17% quarter-over-quarter.
- 18 funds opened new SELLAS Life Sciences positions in Q1 2017 and 8 closed out, a net change of +10 holders.
- The largest SELLAS Life Sciences buyer in Q1 2017 was Sabby Management, an estimated $2.7M added.
- The largest SELLAS Life Sciences seller in Q1 2017 was D.E. Shaw & Co, an estimated $358K sold.
Based on aggregated 13F filings for Q1 2017.